As of September 30, 2025, Immunovant’s (IMVT) cash and cash equivalents totaled approximately $521.9 million, providing runway for announced indications through GD readout expected in 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT: